Mangoceuticals, Inc. Operating Cash Flow
Mangoceuticals, Inc. (MGRX) reported Operating Cash Flow of -$1.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Mangoceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$260.51K.
- Mangoceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.31M.
- Mangoceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.08M.
- Mangoceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.24M.
- Mangoceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$5.85M.
- Mangoceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$4.86M.
- Mangoceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$7.00M.
- Mangoceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$1.35M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$260.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.57M 10-Q · filed 2026-08-13 | -$2.65M derived: sum of 3 quarters · filed 2026-08-13 | -$3.89M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$1.31M 10-Q · filed 2026-05-19 | -$2.39M derived: sum of 2 quarters · filed 2026-05-19 | -$3.63M derived: sum of 3 quarters · filed 2026-05-19 | -$4.89M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$2.32M derived: sum of 2 quarters · filed 2026-04-01 | -$3.58M derived: sum of 3 quarters · filed 2026-08-13 | -$5.85M 10-K · filed 2026-04-01 | |
| 2025-09-30 | -$1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$2.50M derived: sum of 2 quarters · filed 2026-08-13 | -$4.77M 10-Q · filed 2025-11-14 | -$5.90M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$3.53M 10-Q · filed 2026-08-13 | -$4.66M derived: sum of 3 quarters · filed 2026-08-13 | -$5.83M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$2.27M 10-Q · filed 2026-05-19 | -$3.40M derived: sum of 2 quarters · filed 2026-05-19 | -$4.57M derived: sum of 3 quarters · filed 2026-05-19 | -$6.15M derived: sum of 4 quarters · filed 2026-05-19 | |
| 2024-12-31 | -$1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$2.30M derived: sum of 2 quarters · filed 2026-04-01 | -$3.87M derived: sum of 3 quarters · filed 2026-04-01 | -$4.86M 10-K · filed 2026-04-01 | |
| 2024-09-30 | -$1.17M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-11-14 | -$2.74M derived: sum of 2 quarters · filed 2025-11-14 | -$3.73M 10-Q · filed 2025-11-14 | -$5.43M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$1.58M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2025-11-14 | -$2.57M 10-Q/A · filed 2025-11-14 | -$4.27M derived: sum of 3 quarters · filed 2025-11-14 | -$5.98M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-03-31 | -$991.13K 10-Q · filed 2025-05-15 | -$2.69M derived: sum of 2 quarters · filed 2025-05-15 | -$4.40M derived: sum of 3 quarters · filed 2025-05-15 | -$6.18M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$3.41M derived: sum of 2 quarters · filed 2025-03-20 | -$5.19M derived: sum of 3 quarters · filed 2025-03-20 | -$7.00M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$3.49M derived: sum of 2 quarters · filed 2024-11-14 | -$5.30M 10-Q · filed 2024-11-14 | -$5.95M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$3.59M 10-Q · filed 2024-08-14 | -$4.24M derived: sum of 3 quarters · filed 2024-08-14 | -$4.84M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$1.81M 10-Q · filed 2024-05-15 | -$1.81M 10-Q · filed 2023-05-10 | -$2.46M derived: sum of 2 quarters · filed 2024-05-15 | -$3.06M derived: sum of 3 quarters · filed 2024-05-15 | -$3.14M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$649.56K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$1.25M derived: sum of 2 quarters · filed 2024-04-01 | -$1.33M derived: sum of 3 quarters · filed 2024-04-01 | -$1.35M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$600.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-27 | -$678.25K derived: sum of 2 quarters · filed 2023-10-27 | -$696.96K 10-Q · filed 2023-10-27 | ||
| 2022-06-30 | -$77.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | -$96.61K 10-Q · filed 2023-07-28 | |||
| 2022-03-31 | -$18.71K 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |